VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | Fedratinib: MPN-associated myelofibrosis

VJHemOnc is committed to improving our service to you

Jean-Jacques Kiladjian

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines the recent approval of fedratinib, a JAK inhibitor, for patients with myeloproliferative neoplasm (MPN) -associated myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter